Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Activated Jak2 with the V617F point mutation promotes G1/S phase transition.

Christoph Walz1, Brian J Crowley, Heidi E Hudon

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

The Journal of Biological Chemistry
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood advances·2026
Same author

Dual CDK2 and CDK4/6 inhibition suppresses Rb/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemia.

Haematologica·2026
Same author

Beyond attention heatmaps: How to get better explanations for multiple instance learning models in histopathology.

Medical image analysis·2026
Same author

Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC.

BMC cancer·2026
Same author

Spatially resolved ex vivo drug response profiling in SMARCB1-deficient sinonasal carcinoma.

EMBO molecular medicine·2026
Same author

Proximity-Induced Rewiring of Oncogenic Kinase Triggers Apoptosis.

ACS central science·2026

The Jak2V617F mutation in myeloproliferative disorders drives cell growth via STAT5 and reactive oxygen species, affecting cell cycle regulators cyclin D2 and p27(Kip). Targeting these pathways may offer new therapeutic strategies.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Myeloproliferative diseases involve hematopoietic stem cells with abnormal growth factor responses.
  • The Janus kinase 2 (Jak2) V617F mutation is linked to myeloproliferative disorders.
  • Understanding Jak2V617F signaling is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the signaling mechanisms downstream of the Jak2V617F mutation.
  • To elucidate the roles of STAT5, cell cycle regulators, and reactive oxygen species in Jak2V617F-mediated proliferation.
  • To identify potential therapeutic targets for myeloproliferative disorders.

Main Methods:

  • Utilized Jak2V617F mutant-expressing erythroid leukemia cell lines (HEL) and BaF3 cells.
  • Employed small molecule Jak2 inhibitors and small interfering RNA (siRNA) for Jak2 inhibition.

Related Experiment Videos

  • Assessed cell cycle progression, expression of cyclin D2 and p27(Kip), STAT5 activity, and reactive oxygen species (ROS) levels.
  • Investigated the effect of N-acetylcysteine (antioxidant) on cell growth and molecular markers.

    • Main Results:

    • Jak2 inhibition led to G(1) cell cycle arrest, decreased cyclin D2, and increased p27(Kip) expression.
    • STAT5 activation mimicked these effects, suggesting its role downstream of Jak2V617F.
    • Jak2V617F and activated STAT5 increased reactive oxygen species, promoting cell cycle progression.
    • Antioxidant treatment reversed these effects, reducing cell growth and altering cyclin D2/p27(Kip) levels.

    Conclusions:

    • Jak2V617F signaling, via STAT5 and redox balance, regulates cyclin D2 and p27(Kip) to promote cell cycle progression.
    • These findings highlight novel therapeutic targets, including redox pathways, for myeloproliferative disorders.